The True Cost of an IVF Cycle: Unit Economics and What Scale Changes

Most fertility clinics know what they charge for a cycle. Far fewer know what one costs them — and fewer still know how that cost varies between the cycle that produced four oocytes and the one that produced eighteen.

That gap is not a bookkeeping detail. It determines which services are subsidising which, whether a new site will be profitable at the volume it can realistically reach, and whether a package price protects the clinic or quietly erodes it.

What “cost per cycle” actually means

The true cost of an IVF cycle is the sum of the resources that specific cycle consumed: embryologist and clinician time, consumables, a share of incubator and equipment capacity, laboratory overhead, and whichever procedures were actually performed.

It is not the price charged. And it is not total annual cost divided by cycles completed — that produces an average, and no individual cycle is the average.

The distinction matters because clinical variation is large. A retrieval yielding four oocytes and one yielding eighteen occupy the embryology team for materially different lengths of time. Add ICSI to one, a biopsy to another, a freeze-all to a third, and the resource profile diverges further. Billing may treat all three as the same product.

Why flat-rate pricing hides the number

Flat-rate pricing is operationally simple and commercially familiar. It is also, from a costing perspective, a form of averaging that destroys the information you most need.

When every cycle carries the same price and the same assumed cost, three things become invisible:

• Which cycles lose money. High-yield, high-intervention cycles can cost well above the mean while billing the same as a straightforward one.
• Which service lines carry the clinic. Cryostorage, donor programmes and diagnostics have very different cost-to-revenue shapes from a fresh cycle, and blended reporting hides that.
• Whether a discount is affordable. A package or multi-cycle offer priced against an average will be underpriced for exactly the complex cases most likely to use it. The billing mechanics of that are covered in why IVF treatment packages break ordinary billing software.

The clinic is not mispricing out of carelessness. It is pricing against a number that its own systems cannot produce.

What activity-based costing exposes

Activity-based costing takes a different route. Rather than spreading overhead evenly, it assigns cost to the activities a cycle triggers — each retrieval, each fertilisation assessment, each freeze event, each witnessing step — and builds the cycle cost from those components.

A 2025 study published in the Journal of Assisted Reproduction and Genetics applied this method across five United States laboratories, framing it explicitly as a route to cost transparency and operational scaling (Springer).

The reframing is useful on its own. An IVF laboratory behaves less like a clinic department and more like a specialised production facility: fixed capacity, skilled labour, batch-sensitive throughput, and unit costs that move with volume. Most clinics do not price it that way.

The scale finding, and what it implies

The clearest operational result from that work concerns volume.

Laboratories performing around 500 egg collections a year carried roughly 40% higher cost per procedure than laboratories performing around 2,000 — attributed to less efficient utilisation of staff and equipment.

The mechanism is not mysterious. Incubators, witnessing systems, quality programmes and senior embryologist time are largely fixed. Spread across four times the cycles, the per-cycle share falls sharply.

Three consequences follow for clinic leadership:

1. Benchmarking against published averages is misleading unless the comparator operates at your volume. A cost figure from a 2,000-cycle laboratory is not a target for a 500-cycle one; it is a description of a different operating point.
2. Expansion economics are non-linear. A second site does not inherit the parent’s unit costs on day one — it starts at the low-volume end of that curve and works down.
3. Utilisation is a cost lever, not just a capacity metric. Filling existing capacity improves unit cost faster than most procurement savings will.

What varies that a flat rate cannot see

If you intend to measure cost per cycle properly, these are the variables that actually move it:

• Oocytes retrieved — the single largest driver of embryology time per cycle
• Fertilisation method — conventional insemination versus ICSI
• Biopsy and genetic testing — added handling, added witnessing, added coordination with the reference laboratory
• Freeze-all versus fresh transfer — shifts cost into cryo and into future storage obligations
• Cycle cancellation — cost incurred with no billable transfer at the end
• Protocol — monitoring intensity differs, and monitoring is clinician and scanner time

None of these are exotic. All of them are already recorded somewhere in a clinic. The problem is that they are usually recorded in the clinical record while cost sits in the finance system, and nothing joins them per cycle.

What you need in place to measure it

Costing at cycle level is a data-structure problem before it is a finance problem. Three things have to be true:

Procedures must attach to the cycle, not the invoice. If ICSI is a billing line rather than a recorded clinical event on that cycle, you can count the revenue but not the resource.

Consumables and time must be attributable. Not to the minute — but a cycle that used three hours of senior embryologist time should be distinguishable from one that used one.

Reporting must group by the dimensions that matter. Cost by protocol, by clinician, by patient cohort, by site. An annual average tells you nothing you can act on.

In MedART, procedures are recorded against the cycle record itself, so Billing & Insurance draws on the clinical events that actually occurred rather than a separately maintained charge list. AI & Analytics then groups those events by protocol, clinician or site — which is what turns a cost number into a decision. Because both run on the same data model as the rest of MedART, the join happens once, at the point of care, rather than monthly in a spreadsheet.

For the wider argument about why disconnected clinical and financial systems produce numbers too late to use, see data management in fertility clinics. The outcome side of the same reporting problem is covered in the IVF success-rate analytics dashboard.

Where to start

You do not need a costing programme to make progress. You need one honest number.

Take a single month of completed cycles and split them into three groups by oocytes retrieved — low, middle, high. For each group, count the procedures actually performed. You will not have precise cost, but you will see the spread — and the spread is the finding. If your highest-yield cycles carry substantially more work for the same price, you have learned something your annual average was never going to tell you.

That exercise also reveals whether your systems can answer the question at all. Most clinics discover the data exists but cannot be assembled per cycle without manual work. That, rather than the cost figure itself, is usually the thing worth fixing first.